Supported by an educational grant from Novo Nordisk
Many clinicians who manage the care of patients with type 2 diabetes mellitus (T2DM) still lack confidence in the use of GLP-1 receptor agonists (GLP-1 RAs). Despite clear recommendations from national and international guidelines about the safety and efficacy of GLP-1 RAs, clinicians need further guidance on the appropriate selection of these agents for the multidimensional care of a diverse population of T2DM patients.
This activity is the last in a series of 4 designed to bring clinicians up-to-date on the rapidly evolving landscape of treatment for T2DM. Two internationally renowned experts talk about the “now” and the “new” generation of GLP-1 receptor agonists (GLP-1 RAs), focusing on once-weekly formulations, their comparative performance with respect to glycemic efficacy, weight loss, safety, and cardiovascular outcomes, and how the latest, 2018 clinical practice guidelines by the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD), promise to impact clinical decision-making, emphasizing proper patient selection and the importance of shared decision-making.
Primary care (family medicine/internal medicine) MDs, DOs, NPs, PAs, and other providers who care for patients with diabetes.
At the conclusion of this activity, participants should be better able to:
Compare the current and next generation of once-weekly GLP-1 RAs regarding glycemic efficacy, weight-loss efficacy, and safety
Evaluate long-acting GLP-1 RAs in patient with T2DM who do not meet glycemic goals
Engage in a therapeutic alliance with patients applying the principles of shared decision-making in a collaborative model of diabetes care
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Professor Stephen C. Bain, BA, MA, MBBS, MD, PRCP Professor of Medicine (Diabetes) Swansea University Medical School Sketty Swansea, United Kingdom
Prof. Bain receives honoraria, research sponsorship, or grants from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cellnovo, Diartis Pharmaceuticals, Eli Lilly & Co., GlaxoSmithKline, Merck Sharp & Dohme, Napp Pharmaceuticals, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, Servier Laboratoires, and Takeda. He also receives support for the development of educational programs from Cardiff University, Doctors.net, Elsevier, Medscape, OmniaMed, and OnMedica. Dr. Bain is a Stock/Shareholder of Glycosmedia, which carries sponsorship declared on site. Additionally, he is a consultant for All-Wales Medicines Strategy Group and the National Institute for Health and Care Excellence.
Professor Michael A. Nauck, MD Diabetes Centre Bochum-Hattingen Medical Department I St. Josef-Hospital Ruhr-University Bochum, Germany
Prof. Nauck is a consultant for Eli Lilly & Co., Menarini/Berlin-Chemie, Merck Sharp & Dohme, and Novo Nordisk. He receives research support (provided to his institution) from AstraZeneca, Merck Sharp & Dohme, and Novo Nordisk. Dr. Nauck is also on the speakers’ bureaus of AstraZeneca, Eli Lilly & Co., Medscape, Menarini/Berlin-Chemie, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, and Sun Pharma.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
Physician Assistant Continuing Education AAPA accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credit for completing this activity.
Nurse Practitioner Continuing Education AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education (HME), or Novo Nordisk. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.